Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 6—June 2020
CME ACTIVITY - Synopsis

Manifestations of Toxic Shock Syndrome in Children, Columbus, Ohio, USA, 2010–20171

Aliza Cook2, Sarah Janse, Joshua R. Watson, and Guliz ErdemComments to Author 
Author affiliations: The Ohio State University, Columbus, Ohio, USA (A. Cook, S. Janse, J.R. Watson, G. Erdem); Nationwide Children’s Hospital, Columbus (S. Janse, J.R. Watson, G. Erdem)

Cite This Article

Introduction

CME Logo

Medscape CME ACTIVITY

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate.

Release date: May 14, 2020; Expiration date: May 14, 2021

Learning Objectives

Upon completion of this activity, participants will be able to:

•     Evaluate the clinical characteristics of pediatric toxic shock syndrome (TSS) in a large tertiary care center, based on a retrospective chart review

•     Determine diagnostic decisions regarding pediatric TSS in a large tertiary care center, and their implications for published criteria, based on a retrospective chart review

•     Assess the treatment and management of pediatric TSS, based on a retrospective chart review from a large tertiary care center

CME Editor

Karen L. Foster, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Karen L. Foster has disclosed no relevant financial relationships.

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Authors

Disclosures: Aliza Cook, MD; Sarah Janse, PhD; Joshua R. Watson, MD; and Guliz Erdem, MD, have disclosed no relevant financial relationships.

Top

Abstract

Data are limited on the incidence and management of streptococcal toxic shock syndrome (TSS) and nonstreptococcal TSS in children. We aimed to define the clinical patterns of TSS at Nationwide Children’s Hospital in Ohio as they relate to published criteria, diagnostic decisions, and treatment options. Through retrospective chart reviews, we identified 58 patients with TSS (27 streptococcal, 31 nonstreptococcal) during January 2010–September 2017. We observed clinical and laboratory findings that are not part of TSS criteria, such as pyuria in streptococcal TSS (50% of patients) and pulmonary involvement (85%) and coagulopathy (92%) in nonstreptococcal TSS patients. Recommended treatment with clindamycin and intravenous immunoglobulin was delayed in streptococcal TSS patients without rash (3.37 days vs. 0.87 days in patients with rash), leading to prolonged hospitalization and complications. Incorporation of additional TSS signs and symptoms would be helpful in TSS diagnosis and management.

Toxic shock syndrome (TSS) is a severe acute illness caused by toxin-producing strains of Streptococcus pyogenes (streptococcal TSS [STSS]) and Staphylococcus aureus (nonstreptococcal TSS [NSTSS]) (15). Data are limited on the incidence, management, and outcomes for children with TSS (68). Most epidemiologic and clinical studies of TSS have reported predominantly streptococcal cases. The incidence of severe streptococcal infections, including TSS, has been increasing in North America since the 1990s. Studies from the United States and Canada report incidence rates of 3.8–10.24 invasive group A Streptococcus (GAS) cases per 100,000 persons per year (9,10). Reported death rates vary from 4.2% to 56% for STSS (2,3,7,8,1115) and are up to 22% for NSTSS (3,12).

The uncontrolled cytokine stimulation by bacterial toxins results in several clinical manifestations of TSS, such as hypotension, fever, rash, and organ dysfunction (3,8). On the basis of these clinical signs, the Centers for Disease Control and Prevention (CDC) defined criteria for TSS and updated these criteria in 2010 for STSS and in 2011 for NSTSS (4,5). Despite recognition of illness and CDC disease definitions, TSS diagnosis remains challenging because some clinical findings, such as hypotension, could be transient and some, such as rash, might be absent.

CDC criteria do not differentiate between children and adults. In children, differentiating TSS from septic shock, Kawasaki disease with shock, and drug reaction with eosinophilia and systemic symptoms syndrome poses additional challenges (3,16). In addition to these diagnostic difficulties, challenges and controversies exist for managing TSS. Our objective was to differentiate the clinical patterns of TSS in children in a large tertiary center as they relate to published criteria, diagnostic decisions, and treatment options.

Methods

The Nationwide Children’s Hospital Institutional Review Board approved the study. We queried electronic medical records during January 2010–December 2017 for diagnosis codes from the International Classification of Diseases, 10th Revision, for toxic shock syndrome, severe sepsis with septic shock, GAS bacteremia, and necrotizing fasciitis. The addition of diagnoses other than TSS helped us identify 7 STSS patients who were discharged with diagnoses of sepsis and septic shock. In addition to discharge and admission diagnoses, we considered any diagnosis during the hospitalization period associated with these billing codes. We also reviewed preadmission records related to the admission diagnoses. We included patients in the study if their illness met criteria for definite or probable TSS. Where all CDC criteria for either STSS or NSTSS were fulfilled, we defined cases as definite (4,5). Where a single criterion was missing because of incomplete data or because GAS was isolated from a nonsterile site, we classified the case as probable (4). Data collected were age, sex, height, weight, body mass index, date of presentation, and clinical signs and symptoms (Table 1). We also collected duration of hospitalization; use and type of antimicrobial agents; use and timing of clindamycin, intravenous immunoglobulin (IVIg), or both after initial evaluation; and clinical outcomes, including mechanical intubation, amputation, and death. We reviewed several admission laboratory and radiologic parameters: complete blood count, urinalysis, blood urea nitrogen, creatinine, estimated glomerular filtration rate, alanine transaminase, aspartate transaminase, total bilirubin, creatinine kinase, coagulation studies, and chest radiographs. We also reviewed additional studies and any imaging study done during the hospitalization period that identified possible sites and sources of infection.

Statistical Analysis

We compared the demographic, clinical, laboratory, and treatment data between patients with STSS and NSTSS. We used Student t tests to compare normally distributed continuous variables between STSS and NSTSS groups, the Wilcoxon rank-sum test to analyze skewed continuous variables, and a Fisher exact test to analyze categorical variables. Continuous variables are presented as means with SDs for normally distributed variables and as median and interquartile range for skewed variables; categorical variables are presented as counts with percentages.

We conducted all analyses on log-transformed values of the time from admission outcomes to satisfy model assumptions. We used Student t tests to compare STSS with NSTSS and a linear mixed model to compare groups of antimicrobial drugs. For ease of interpretation, raw means and SDs are presented for each group, and the mean difference of the log-transformed values are presented as the ratio of geometric means with 95% CI.

Results

During the study period, 456 patients had diagnosis codes of TSS, severe sepsis with septic shock, GAS bacteremia, and necrotizing fasciitis at admission, discharge, or both. Our review of electronic medical records indicated that illnesses of 58 patients met the CDC diagnostic criteria for TSS. None of the patients had a prolonged preadmission course that would affect their treatment start time. Twenty-seven (47%) patients had STSS and 31 (53%) had NSTSS. Of the STSS patients, 16 had confirmed and 11 had probable STSS. Of the NSTSS patients, 11 had confirmed and 20 had probable NSTSS.

Clinical and Laboratory Findings

Fever was not always documented during initial examinations, although most patients had history of fever requiring antipyretic medication or had fever develop during hospitalization (Table 1). Vomiting and rash were present in most patients with TSS. However, of the 27 patients with STSS, 13 (48%) had no rash. Altered mental status was observed in ≈40% of patients.

Of patients with confirmed STSS, GAS was isolated from blood (3 patients), deep tissue (4 patients from necrotic tongue, subdural empyema, orbital abscess, and sinus aspirations), pleural fluid and deep endotracheal tube suction (4 patients), peritoneal fluid (1 patient), endotracheal tube suction and blood (3 patients), and urine and blood (1 patient). Patients with probable STSS had GAS obtained from rapid streptococcal screening test and throat cultures. Patients with NSTSS had staphylococci isolated from skin lesions and abscesses (10 patients); sterile sites, including bone (3 patients); urine (1 patient); and vaginal and genital area swab samples (7 patients).

Several patients with NSTSS, for which only thrombocytopenia is listed in the hematologic category of the CDC definition, had other coagulation abnormalities. Of 25 patients who had coagulation tests on admission, 17 (68%) had increased prothrombin time, 7 (28%) had increased prothrombin and partial thromboplastin time, and 1 patient had prolonged partial thromboplastin time.

Inflammatory markers were not tested in all patients at admission. For the 20 patients for whom erythrocyte sedimentation rate (ESR) was tested on admission, median ESR was 22 mm/h (IQR 15.0–36.0 mm/h; reference 0–13 mm/h). ESR levels were higher in patients with STSS. Of 15 patients with NSTSS, median ESR was 22 mm/h (IQR 15.0–32.5 mm/h); of 5 patients with STSS, median ESR was 36 mm/h (IQR 14.5–39 mm/h). Of 34 patients for whom C-reactive protein (CRP) was tested on admission, median CRP was 12.75 mg/dL (IQR 6.8–23.8 mg/dL; reference <1.2 mg/dL). Of 18 patients with NSTSS, median CRP was 8.3 mg/dL (IQR 5.8–20.6 mg/dL), and of 16 patients with STSS, median CRP was 20.4 mg/dL (IQR 6.9–26.3mg/dL). CRP levels were significantly higher for patients with STSS than for those with NSTSS (p = 0.0443).

Pulmonary infiltrates were present in most (42 patients) patients with TSS at diagnosis and admission. Only 7 (12%) patients had primary admission and discharge diagnoses for pneumonia. Median arterial oxygen partial pressure to fractional inspired oxygen (PaO2:FiO2) ratio was also decreased in these patients. Of the 31 patients with NSTSS, for which pulmonary involvement is not a CDC diagnostic criterion, 19 (61%) had diffuse pulmonary infiltrates.

Of the clinical criteria listed for TSS and NSTSS and evaluated on admission, creatine phosphokinase was not elevated in the 17 patients for whom results were available. Similarly, renal and hepatic involvement criteria for both STSS and NSTSS did not vary significantly from age-based normal values for most of the patients. Twelve (21%) patients had elevated alanine transaminase, 14 (24%) had elevated aspartate transaminase, and 17 (29%) had elevated serum creatinine. However, pyuria (>10 leukocytes/high-power field), which is not a CDC clinical criterion for STSS, was present in half the patients with STSS who had a urinalysis on admission (median urine leukocyte count 17.5/high-power field). We also reviewed microbiological studies. For 21 (68%) patients with NSTSS, Staphylococcus aureus grew from superficial and sterile site cultures.

We found significant differences between patients with STSS and NSTSS. Patients with STSS were significantly younger, had lower body mass index, were less likely to have an erythematous rash, and had more capillary leak and pulmonary infiltrates at presentation. Patients with NSTSS were less likely to have pulmonary infiltrates and capillary leak and to have less tissue necrosis or mental status changes (Table 1).

Management of Patients

Patients with NSTSS received clindamycin and IVIg sooner than patients with STSS. Five patients who did not receive clindamycin or IVIg had STSS. Patients with NSTSS stayed ≈57% fewer inpatient days (Tables 1, 2; Appendix). One patient had necrotizing infection of the tongue that was promptly recognized and operatively debrided. One patient with STSS died. We examined the differences between patients receiving only clindamycin, only IVIg, both, or neither. None of the outcomes differed significantly among groups (Appendix).

Management of STSS patients with rash differed from management of those without rash. We found no difference in the requirement for vasopressor support between patients with or without rash, yet clindamycin was initiated ≈66% sooner for patients with rash than for patients without rash (Table 2). Patients with STSS and without a rash had longer hospital stays than did those with rash. Clindamycin with or without IVIg infusion was delayed in treatment of STSS patients without rash, and for 5 patients (19% of patients without rash), neither clindamycin nor IVIg was administered.

Discussion

Data are limited on the incidence and management of children with TSS (3,8). Our large, single-institution retrospective analysis of 58 cases showed similarities and unexpected findings among children with TSS. In comparison with patients with NSTSS, children with STSS were younger, experienced more severe illness with higher rates of capillary leak and pulmonary symptoms, and had longer hospital stays. Similar to our findings, STSS has been associated with more severe disease and worse outcomes than NSTSS in the literature (2,3,7,8,15,17). Unlike our findings, those studies do not indicate whether late recognition and treatment of STSS in patients without rash played any role in the reported disease outcomes and hospitalization duration.

Case definitions for streptococcal and NSTSS are generally designed to optimize specificity rather than sensitivity. Our data suggest that unified criteria for TSS, rather than separate criteria for STSS and NSTSS, might improve sensitivity. We found that certain clinical and laboratory findings were common in both STSS and NSTSS but only included in the case definition of one or the other. First, although pyuria is a criterion for NSTSS but not for STSS (4,5), half the urinalyses performed in both groups demonstrated pyuria. Second, acute respiratory distress syndrome is a criterion for STSS but not for NSTSS. However, 61% of the patients in our study with NSTSS had diffuse pulmonary infiltrates and decreased PaO2:FiO2 ratio <200. Finally, coagulation abnormalities are included in the case definition of STSS but not NSTSS, yet most patients in both groups had abnormalities. The pulmonary involvement, pyuria, and coagulation abnormalities were common and were observed at admission. Case definitions are generally designed to have high specificity, sometimes at the expense of sensitivity. If the relatively inexpensive evaluation methods, such as urinalysis, chest radiograph, PaO2:FiO2 ratio of <200 and coagulation panels were incorporated into TSS evaluations, our data suggest that they might have aided accurate and timely diagnosis. Consideration of these additional organ dysfunctions, and considering TSS as a unifying diagnosis rather than as STSS and NSTSS, could potentially strengthen the conclusive diagnosis rather than discrediting it.

Data from published literature illustrate the importance of prompt recognition of TSS and early treatment (7,1824). Complementary treatment with clindamycin improves the survival of patients with STSS by reducing toxin release (7,1824). Although IVIg is suggested as a possible adjunctive agent, published patient outcomes have varied (2428). IVIg functions by inhibiting T-cell activation that would result in decreased cytokine release, down-regulation of adhesion molecules, chemokine and chemokine-receptor expression, and neutralization of superantigens (2528). In some studies, IVIg did not show significant benefit in treatment of patients with STSS (20,24,29). One report that pooled 5 studies of clindamycin and IVIg treatment for STSS showed the death rates decreased from 33.7% to 15.7% (30). We did not identify significant differences in hospitalization rates and duration of mechanical ventilation among patients treated with or without IVIg. Fewer than half the patients in our study received clindamycin and IVIg. Similarly, only 50%–67% of patients with severe GAS infection have received clindamycin (2,18,20,24). Our results suggest that the lack of appropriate treatment may be associated with absence of rash at the time of presentation. In our study, in STSS patients without rash, sepsis alone was often diagnosed, and the patients were not treated with clindamycin or IVIg. These patients also experienced delays in diagnosis and had longer hospital stays than those with a rash.

Our study had several limitations. Although Nationwide Children’s Hospital serves almost all of central Ohio’s children, our data were not population based and were from 1 pediatric center. We might not have identified all patients with NSTSS because we were unable to review individual charts for patients with staphylococcal bacteremia if they did not have additional diagnoses of sepsis or septic shock. Despite our efforts to capture the clinical and laboratory changes at the time of initial evaluation, the duration of illness, as well as rapidly changing signs such as rash, might not have been accurately recorded in the patient charts, which would affect the overall diagnosis and possibly lead to misclassification of patients. In addition, because of the retrospective nature of our study, none of the bacterial isolates were archived for further typing or microbiological analysis.

Our findings indicate organ system involvement in TSS beyond that predicted by existing CDC criteria. Because clinicians appear to rely on archetypal presentations of TSS (e.g., fever, hypotension, and rash) to diagnose TSS, updated clinical and diagnostic criteria would facilitate early accurate diagnosis and treatment. Physicians should be aware of TSS presentations without rash. Furthermore, the updated criteria may benefit from a unifying definition.

Dr. Cook is an internal medicine resident at Yale New Haven Hospital in New Haven, Connecticut. Her primary research interests include primary care innovations, hospital-to-home transitions, quality improvement, and health equity.

Top

References

  1. Stevens  DL, Tanner  MH, Winship  J, Swarts  R, Ries  KM, Schlievert  PM, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989;321:17. DOIPubMed
  2. Adalat  S, Dawson  T, Hackett  SJ, Clark  JE; In association with the British Paediatric Surveillance Unit. Toxic shock syndrome surveillance in UK children. Arch Dis Child. 2014;99:107882. DOIPubMed
  3. Javouhey  E, Bolze  PA, Jamen  C, Lina  G, Badiou  C, Poyart  C, et al. Similarities and differences between staphylococcal and streptococcal toxic shock syndromes in children: results from a 30-case cohort. Front Pediatr. 2018;6:360. DOIPubMed
  4. Centers for Disease Control and Prevention. Streptococcal toxic shock syndrome (STSS) (Streptococcus pyogenes) 2010 case definition [cited 2019 May 23]. https://wwwn.cdc.gov/nndss/conditions/streptococcal-toxic-shock-syndrome/case-definition/2010
  5. Centers for Disease Control and Prevention. Toxic shock syndrome (other than streptococcal) (TSS) 2011 case definition [cited 2019 May 23]. https://wwwn.cdc.gov/nndss/conditions/toxic-shock-syndrome-other-than-streptococcal/case-definition/2011
  6. O’Brien  KL, Beall  B, Barrett  NL, Cieslak  PR, Reingold  A, Farley  MM, et al. Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin Infect Dis. 2002;35:26876. DOIPubMed
  7. Chen  KY, Cheung  M, Burgner  DP, Curtis  N. Toxic shock syndrome in Australian children. Arch Dis Child. 2016;101:73640. DOIPubMed
  8. Chuang  YY, Huang  YC, Lin  TY. Toxic shock syndrome in children: epidemiology, pathogenesis, and management. Paediatr Drugs. 2005;7:1125. DOIPubMed
  9. Nelson  GE, Pondo  T, Toews  KA, Farley  MM, Lindegren  ML, Lynfield  R, et al. Epidemiology of invasive group A streptococcal infections in the United States, 2005–2012. Clin Infect Dis. 2016;63:47886. DOIPubMed
  10. Tyrrell  GJ, Fathima  S, Kakulphimp  J, Bell  C. Increasing rates of invasive group A streptococcal disease in Alberta, Canada; 2003–2017. Open Forum Infect Dis. 2018;5:ofy177. DOIPubMed
  11. Davies  HD, Matlow  A, Scriver  SR, Schlievert  P, Lovgren  M, Talbot  JA, et al. Apparent lower rates of streptococcal toxic shock syndrome and lower mortality in children with invasive group A streptococcal infections compared with adults. Pediatr Infect Dis J. 1994;13:4956. DOIPubMed
  12. Descloux  E, Perpoint  T, Ferry  T, Lina  G, Bes  M, Vandenesch  F, et al. One in five mortality in non-menstrual toxic shock syndrome versus no mortality in menstrual cases in a balanced French series of 55 cases. Eur J Clin Microbiol Infect Dis. 2008;27:3743. DOIPubMed
  13. Rodríguez-Nuñez  A, Dosil-Gallardo  S, Jordan  I; ad hoc Streptococcal Toxic Shock Syndrome collaborative group of Spanish Society of Pediatric Intensive Care. Clinical characteristics of children with group A streptococcal toxic shock syndrome admitted to pediatric intensive care units. Eur J Pediatr. 2011;170:63944. DOIPubMed
  14. Shah  SS, Hall  M, Srivastava  R, Subramony  A, Levin  JE. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis. 2009;49:136976. DOIPubMed
  15. Timmis  A, Parkins  K, Kustos  I, Riordan  FA, Efstratiou  A, Carrol  ED. Invasive group A streptococcal infections in children presenting to a paediatric intensive care unit in the North West of England. J Infect. 2010;60:1836. DOIPubMed
  16. Lin  YJ, Cheng  MC, Lo  MH, Chien  SJ. Early differentiation of Kawasaki disease shock syndrome and toxic shock syndrome in a pediatric intensive care unit. Pediatr Infect Dis J. 2015;34:11637. DOIPubMed
  17. Lithgow  A, Duke  T, Steer  A, Smeesters  PR. Severe group A streptococcal infections in a paediatric intensive care unit. J Paediatr Child Health. 2014;50:68792. DOIPubMed
  18. Linnér  A, Darenberg  J, Sjölin  J, Henriques-Normark  B, Norrby-Teglund  A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 2014;59:8517. DOIPubMed
  19. Andreoni  F, Zürcher  C, Tarnutzer  A, Schilcher  K, Neff  A, Keller  N, et al. Clindamycin affects group A streptococcus virulence factors and improves clinical outcome. J Infect Dis. 2017;215:26977.PubMed
  20. Couture-Cossette  A, Carignan  A, Mercier  A, Desruisseaux  C, Valiquette  L, Pépin  J. Secular trends in incidence of invasive beta-hemolytic streptococci and efficacy of adjunctive therapy in Quebec, Canada, 1996-2016. PLoS One. 2018;13:e0206289. DOIPubMed
  21. Stevens  DL, Gibbons  AE, Bergstrom  R, Winn  V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158:238. DOIPubMed
  22. Sriskandan  S, McKee  A, Hall  L, Cohen  J. Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J Antimicrob Chemother. 1997;40:2757. DOIPubMed
  23. Zimbelman  J, Palmer  A, Todd  J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J. 1999;18:1096100. DOIPubMed
  24. Carapetis  JR, Jacoby  P, Carville  K, Ang  SJ, Curtis  N, Andrews  R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis. 2014;59:35865. DOIPubMed
  25. Norrby-Teglund  A, Muller  MP, Mcgeer  A, Gan  BS, Guru  V, Bohnen  J, et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis. 2005;37:16672. DOIPubMed
  26. Schlievert  PM. Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses. J Allergy Clin Immunol. 2001;108(Suppl):S10710. DOIPubMed
  27. Valiquette  L, Low  DE, McGeer  AJ. Assessing the impact of intravenous immunoglobulin in the management of streptococcal toxic shock syndrome: a noble but difficult quest. Clin Infect Dis. 2009;49:13779. DOIPubMed
  28. Low  DE. Toxic shock syndrome: major advances in pathogenesis, but not treatment. Crit Care Clin. 2013;29:65175. DOIPubMed
  29. Kadri  SS, Swihart  BJ, Bonne  SL, Hohmann  SF, Hennessy  LV, Louras  P, et al. Impact of intravenous immunoglobulin on survival in necrotizing fasciitis with vasopressor-dependent shock: a propensity score-matched analysis from 130 US hospitals. Clin Infect Dis. 2017;64:87785.PubMed
  30. Parks  T, Wilson  C, Curtis  N, Norrby-Teglund  A, Sriskandan  S. Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis. Clin Infect Dis. 2018;67:14346. DOIPubMed

Top

Tables

Top

Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to http://www.medscape.org/journal/eid. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.

You must be a registered user on http://www.medscape.org. If you are not registered on http://www.medscape.org, please click on the “Register” link on the right hand side of the website.

Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@medscape.net. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to https://www.ama-assn.org. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Article Title:
Manifestations of Toxic Shock Syndrome in Children, Columbus, Ohio, USA, 2010–2017

CME Questions

1.   Your patient is a 2-year-old boy who appears to have some findings consistent with toxic shock syndrome (TSS), but who has no rash. On the basis of a retrospective chart review from a large tertiary care center by Cook and colleagues, which one of the following statements about clinical characteristics of pediatric TSS is correct?

A. Three quarters of patients with STSS had a characteristic rash

B. One quarter of patients had clinical and laboratory findings that are not part of TSS criteria

C. Pulmonary infiltrates were present in 73% of patients with TSS at diagnosis and admission, but only 12% of patients had primary admission and discharge diagnosis of pneumonia

D. In patients with nonstreptococcal TSS (NSTSS), thrombocytopenia was the only coagulation abnormality identified

2.   According to the retrospective chart review by Cook and colleagues, which one of the following statements about diagnostic decisions regarding pediatric TSS in a large tertiary care center and their implications for published criteria is correct?

A. The findings support existing CDC criteria for TSS diagnosis and management.

B. Clinicians often rely incorrectly on typical presentations of TSS (eg, fever, hypotension, and rash) before they make the diagnosis of TSS

C. The findings support separate diagnostic criteria for STSS and NSTSS

D. The findings support use of diagnostic criteria regarding creatine phosphokinase (CPK) and renal and hepatic involvement

3.   On the basis of the retrospective chart review from a large tertiary care center by Cook and colleagues, which one of the following statements about treatment and management of pediatric TSS is correct?

A. Many patients had a prolonged preadmission course that could delay their treatment start time

B. Treatment with clindamycin and intravenous immunoglobulin (IVIg) led to significantly better outcomes than treatment with IVIg alone

C. Presence or absence of rash did not affect timing of recommended treatment initiation in patients with STSS

D.        Patients with NSTSS received clindamycin and IVIg sooner than those with STSS and stayed ~57% fewer inpatient days

Top

Cite This Article

DOI: 10.3201/eid2606.190783

Original Publication Date: May 14, 2020

1Preliminary results from this study were presented at the Pediatric Academic Societies Meeting, May 6–9, 2017, San Diego, California, USA; and at IDWeek 2018, October 3–7, 2018, San Francisco, California, USA.

2Current affiliation: Yale New Haven Hospital, New Haven, Connecticut, USA.

Related Links

Table of Contents – Volume 26, Number 6—June 2020

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Guliz Erdem, Nationwide Children’s Hospital, 700 Children’s Dr, Columbus, OH 43205, USA

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: May 14, 2020
Page updated: May 14, 2020
Page reviewed: May 14, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external